Showing 2301-2310 of 10214 results for "".
The Biggest Developments in Dermatology: Drs. Tsao and Friedlander Provide Updates at Maui Derm
https://practicaldermatology.com/issues/january-february-2025/the-biggest-developments-in-dermatology-drs-tsao-and-friedlander-provide-updates-at-maui-derm/32937/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, adopted a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Part 6, 1726 nm lasers: Growing the market for the 1726 nm wavelength lasers
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24344/Chapter 6 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the growing the market for the 1726 nm wavelength lasers.Promising Therapies on the Atopic Dermatitis Horizon
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37178/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important potential developments in the atopic dermatitis pipelineISDPA: Dr. Bhatia on JAK Inhibitors
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.Quality of Life and the Mental Toll of Itch
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37179/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, addresses the psychological impact of itch and how it can affect a patient’s overall quality of life.Origins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).Long-Term Bimzelx Data Presented
https://practicaldermatology.com/series/dermwire-tv/long-term-bimzelx-data-presented/35563/In this week's DermwireTV, new long-term data is presented for Bimzelx (bimekizumab-bkzx) for two indications; an analysis examines the correlation between proximity to tanning facilities and melanoma incidence; and in our C-Suite Chats feature, we hear from the Founder and CEO of Joya Health.New Hope for Patients with Onychomycosis
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/new-hope-for-patients-with-onychomycosis/33161/Onychomycosis, a non-self-healing fungal infection of the toenails or fingernails, is a common infection accounting for 20% of all nail diseases in adults, affecting 5% of the worldwide population.What's New in Atopic Dermatitis?
https://practicaldermatology.com/programs/practical-dermatology/whats-new-in-atopic-dermatitis/33014/Emma Guttman, MD, PhD, professor and chair of dermatology at Mount Sinai, talks about the latest developments in treatments and therapies for atopic dermatitis.FDA Approves Botox for Vertical Platysma Bands
https://practicaldermatology.com/series/dermwire-tv/fda-approves-botox-vertical-platysma-bands/29127/In this week's DermwireTV, Botox is approved for its fourth aesthetic indication in the US; the FDA clears a new laser for the long-term treatment of patients with acne vulgaris; and the Chief Scientific Officer of Leo Pharma talks about treatment options for chronic hand eczema.